Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 100
Summary
- Conditions
- Lung Non-Small Cell Squamous Carcinoma
- Stage IV Lung Cancer AJCC v8
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To determine the recommended phase 2 dose (RP2D) of carboplatin in combination with berzosertib (M6620) and gemcitabine/pembrolizumab, in patients with squamous cell non-small cell lung cancer (Sq-NSCLC). (Lead-in Phase 1B) II. To compare progression-free survival (PFS) of car...
PRIMARY OBJECTIVES: I. To determine the recommended phase 2 dose (RP2D) of carboplatin in combination with berzosertib (M6620) and gemcitabine/pembrolizumab, in patients with squamous cell non-small cell lung cancer (Sq-NSCLC). (Lead-in Phase 1B) II. To compare progression-free survival (PFS) of carboplatin/gemcitabine/pembrolizumab with and without M6620 in patients with Sq-NSCLC, as measured by a hazard ratio in an intent-to-treat analysis. (Phase 2) SECONDARY OBJECTIVES: I. To compare progression-free survival (PFS) of carboplatin/gemcitabine/pembrolizumab with and without M6620 in patients with Sq-NSCLC, as measured by a hazard ratio in an as-treated analysis. II. To compare PFS of carboplatin/gemcitabine/pembrolizumab with and without M6620 in patients with ataxia telangiectasia mutated (ATM)-deficient Sq-NSCLC, as measured by a hazard ratio. III. To compare overall survival (OS) and overall response rate (ORR) of carboplatin/gemcitabine/pembrolizumab with and without M6620, in patients with chemotherapy-naive Sq-NSCLC. IV. To determine the systemic drug exposure of M6620 and gemcitabine, as correlates of efficacy and toxicity. V. To determine the safety and tolerability of M6620 in combination with carboplatin/gemcitabine/pembrolizumab. VI. To observe and record anti-tumor activity. EXPLORATORY OBJECTIVES: I. To identify molecular subpopulations of patients who have increased sensitivity to the M6620/carboplatin/gemcitabine/pembrolizumab combination. II. To explore the prognostic and predictive qualities of the ATM immunohistochemistry (IHC) assay for clinical response and PFS. III. To explore inflammation-associated gene signatures and clinical response. OUTLINE: This is a phase Ib, dose de-escalation study of carboplatin followed by a phase II study. Patients are randomized to 1 of 2 arms. ARM A: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes on day 1 and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab alone IV over 30 minutes on day 1. Cycles repeat every 6 weeks for up to 1 more year in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive pembrolizumab, gemcitabine hydrochloride, and carboplatin as in Arm A. After completion of study treatment, patients are followed up for 12 months.
Tracking Information
- NCT #
- NCT04216316
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Liza C Villaruz University of Pittsburgh Cancer Institute LAO